Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. DNLI
stocks logo

DNLI

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.739
+25.21%
--
--
-0.767
+21.73%
--
--
-0.768
+14.69%
Estimates Revision
The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -27.27% over the past three months. During the same period, the stock price has changed by 16.72%.
Revenue Estimates for FY2025
Revise Downward
down Image
-27.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.54%
In Past 3 Month
Stock Price
Go Up
up Image
+16.72%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 32.44 USD with a low forecast of 27.00 USD and a high forecast of 40.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 14.870
sliders
Low
27.00
Averages
32.44
High
40.00
up Image0
Current: 14.870
sliders
Low
27.00
Averages
32.44
High
40.00
BofA
Tazeen Ahmad
Buy
downgrade
$28 -> $27
2025-05-19
Reason
BofA
Tazeen Ahmad
Price Target
$28 -> $27
2025-05-19
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi' as it expects a launch in early 2026, the analyst noted.
Baird
Outperform -> NULL
downgrade
$30 -> $29
2025-05-08
Reason
Baird
Price Target
$30 -> $29
2025-05-08
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Denali Therapeutics to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.
B. Riley
Mayank Mamtani
Buy
downgrade
$35 -> $30
2025-05-08
Reason
B. Riley
Mayank Mamtani
Price Target
$35 -> $30
2025-05-08
downgrade
Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Denali Therapeutics to $30 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm updated the company's model. FDA-related uncertainty continues to weigh on the stock, but attainment of regulatory and pipeline execution milestones in coming months, alongside visibility into new FDA leadership staff taking form, could bode well for Denali, the analyst tells investors in a research note.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$30 → $28
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$30 → $28
2025-03-10
Maintains
Strong Buy
Reason
Morgan Stanley
Matthew Harrison
Buy
Initiates
$41 → $33
2025-03-07
Reason
Morgan Stanley
Matthew Harrison
Price Target
$41 → $33
2025-03-07
Initiates
Buy
Reason
B. Riley Securities
Mayank Mamtani
Strong Buy
Reiterates
$38 → $35
2025-03-05
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$38 → $35
2025-03-05
Reiterates
Strong Buy
Reason
B. Riley lowered the firm's price target on Denali Therapeutics to $35 from $38 and keeps a Buy rating on the shares following the Q4 report. The company highlighted key corporate priorities aimed at de-risking the path to U.S. FDA approvals for multiple programs within its Enzyme Transport Vehicle franchise, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -4.80, compared to its 5-year average forward P/E of -13.13. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.13
Current PE
-4.80
Overvalued PE
0.21
Undervalued PE
-26.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.68
Current EV/EBITDA
-2.36
Overvalued EV/EBITDA
-0.95
Undervalued EV/EBITDA
-20.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
61.15
Current PS
78.58
Overvalued PS
101.78
Undervalued PS
20.51

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
Bought

DNLI News & Events

Events Timeline

(ET)
2025-07-07
10:54:26
Denali noted no FDA panel meeting in call with William Blair
select
2025-07-07
08:02:22
Denali announces FDA acceptance, priority review for tividenofusp alfa BLA
select
2025-05-06 (ET)
2025-05-06
16:12:15
Denali Therapeutics reports Q1 EPS (78c), consensus (70c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
07-10NASDAQ.COM
LABU's Holdings Imply 58% Gain Potential
  • ETF Analysis: The Direxion Daily S&P Biotech Bull 3X Shares ETF (LABU) has an implied analyst target price of $105.45, indicating a potential upside of 57.51% from its current trading price of $66.95.

  • Stock Performance Insights: Notable underlying holdings such as IDEAYA Biosciences, Denali Therapeutics, and Replimune Group show significant upside potential based on analysts' target prices, raising questions about the validity and optimism of these projections.

Preview
9.0
07-07NASDAQ.COM
Denali: FDA To Review BLA Seeking Accelerated Approval For Tividenofusp Alfa
  • FDA Review Acceptance: Denali Therapeutics has received FDA acceptance for its Biologics License Application for tividenofusp alfa, aimed at treating Hunter syndrome, with a target action date of January 5, 2026.

  • Potential Impact: If approved, tividenofusp alfa could represent a significant advancement in enzyme replacement therapy for Hunter syndrome, offering potential benefits for tissue delivery throughout the brain and body.

Preview
6.5
06-09NASDAQ.COM
Analysts Anticipate VB To Hit $270
  • Vanguard Small-Cap ETF Analysis: The Vanguard Small-Cap ETF (VB) has an implied analyst target price of $270.32, indicating a potential upside of 16.07% from its current trading price of $232.89.

  • Notable Holdings with Upside Potential: Key holdings within VB, such as Denali Therapeutics Inc, Azenta Inc, and Vimeo Inc, show significant upside potential based on analyst target prices, raising questions about the accuracy and optimism of these targets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Denali Therapeutics Inc (DNLI) stock price today?

The current price of DNLI is 14.87 USD — it has increased 4.94 % in the last trading day.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s business?

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

arrow icon

What is the price predicton of DNLI Stock?

Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 32.44 USD with a low forecast of 27.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

Denali Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

Denali Therapeutics Inc. EPS for the last quarter amounts to -0.78 USD, increased 14.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Denali Therapeutics Inc (DNLI)'s fundamentals?

The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -27.27% over the past three months. During the same period, the stock price has changed by 16.72%.
arrow icon

How many employees does Denali Therapeutics Inc (DNLI). have?

Denali Therapeutics Inc (DNLI) has 422 emplpoyees as of July 17 2025.

arrow icon

What is Denali Therapeutics Inc (DNLI) market cap?

Today DNLI has the market capitalization of 2.16B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free